Targeting Progressive Chronic Lymphocytic Leukemia
Name of the Trial
Why Is This Trial Important?
Some patients with CLL, however, develop a more rapidly progressive form of the disease that often proves resistant to standard treatment. The average survival of these individuals is less than 24 months following diagnosis.
In this study, researchers are testing the effectiveness of an immunotoxin called LMB-2 in selectively killing CLL cells. LMB-2 is a laboratory-created monoclonal antibody fragment attached to a bacterial toxin. LMB-2 binds to a protein called CD25, which is found on the surface of many human lymphocytes. CD25 is more abundant on CLL cells than on normal lymphocytes, thereby allowing malignant cells to be targeted with great specificity. Once LMB-2 binds to CD25 on the cell surface, the toxin is taken up by the lymphocytes, causing them to die.
Patients enrolled in the study will receive up to 6 courses of LMB-2 over approximately 6 months, providing their disease does not worsen. If and when patients respond completely to LMB-2 (CLL is undetected), they will be given 2 additional courses of treatment.
Who Can Join This Trial?
Where Is This Trial Taking Place?
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.